ImmunityBio receives US FDA's regenerative medicine advanced therapy designation for Anktiva and CAR─NK for metastatic ...
ImmunityBio, Inc, a leading biotechnology company addressing cancer and infectious diseases by bolstering the natural immune system, announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva and CAR-NK (PD-L1 t- …